Rapport Therapeutics (RAPP) Non Operating Income (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Non Operating Income data on file, last reported at $4.4 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $4.4 million, up 43.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 11.68% YoY), and the FY2025 annual result was $13.6 million, up 186.77% from the prior year.
• Non Operating Income eased to $4.4 million in Q1 2026 per RAPP's latest filing, from $4.7 million in the prior quarter.
• Over five years, Non Operating Income peaked at $4.7 million in Q4 2025 and troughed at -$5.6 million in Q1 2024.
• A 4-year average of $2.1 million and a median of $2.9 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 1112.22% in 2024, then declined 25.4% in 2025.
• A 4-year view of Non Operating Income shows it stood at $1.3 million in 2023, then surged by 176.42% to $3.5 million in 2024, then jumped by 34.03% to $4.7 million in 2025, then declined by 8.18% to $4.4 million in 2026.
• Business Quant data shows RAPP's Non Operating Income at $4.4 million in Q1 2026, $4.7 million in Q4 2025, and $3.1 million in Q3 2025.